Greetings. I am the CEO of Medytox, Hyunho Jung.
As the first botulinum toxin developer in Korea, we feel a sense of pride and responsibility for leading this industry. By pushing for presenting more objective and scientific guideline, we are leading in the efforts to make Korean biopharmaceutical industry more transparent and competitive.
Also, with continual in-house R&D, we are the only company in the world to develop three different types of botulinum toxin products "Meditoxin", "Innotox", "Coretox", each with its own unique strengths. Along with these products, Medytox has introduced a synergistic hyaluronic acid filler "Neuramis" with its exclusive technology, successfully solidifying the new pipeline. Furthermore, we are now ready for a great leap forward, as all the establishment from Medytox Plant I, Plant II, Plant III to Medytox R&D Center(Gwanggyo), and Medytox Building in Seoul was constructed.
Medytox will stand among the top 20 global biopharmaceutical companies.
As a young global biopharmaceutical company established in 2000, we set a goal of entering the ‘Top 20 list of global biopharmaceutical companies’ by 2022. Going forward, Medytox will strive to tackle the advanced markets and to directly penetrate and expand into the emerging markets. We will create meaningful performance with new businesses by increasing investment in R&D and pushing continuous commercialization.
We hope this website can provide you with a chance to learn more about Medytox. We ask you for various opinions and continuous support.
Medytox CEO, Hyunho Jung.